Epidemiology of High-risk HPV Infection in Women Participating in a Pilot Screening Program for Cervical Cancer (Epi-START)

CHU de Reims

Status: Completed

Conditions: HPV Infection

Treatments: Biological: Human papillomavirus genotyping

Study type: Observational

Funder types: Other

Identifiers

NCT02809352

PJ12078

Details and patient eligibility

About

Cervical cancer is due to a persistent infection with a group of viruses known as high-risk Human Papillomaviruses (hrHPV). Viral DNA can be easily detected in a cervical sample by a procedure called 'HPV testing', which can be used as a relevant screening test. A pilot screening program called START-HPV has been set up in the Ardennes, a French administrative area localized in the North of France, with HPV testing as a primary screening test.This observational study aimed to evaluate hrHPV genotypes repartition in the population who participate in the START-HPV screening program. This study will allow a better knowledge of hrHPV infection epidemiology in a screened population.

Enrollment: 348 patients

Sex: Female

Ages: 31 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• to live in the Ardennes department (France)
• affiliation to a health insurance organism
• 31 to 65 years old

Exclusion criteria

• current follow-up for cervical cytological abnormalities
• history of hysterectomy
• reimbursement for a Pap smear in the last 3 years

Trial design

348 participants in 1 patient group

women tested positive for hrHPV

Description:

All women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).

Treatment:

Biological: Human papillomavirus genotyping